TDP-43 pathology induces CD8+ T cell activation through cryptic epitope recognition

This study reveals that TDP-43 pathology in ALS and IBM triggers the expression of cryptic peptides, such as those from HDGFL2 and IGLON5, which act as neo-antigens recognized by clonally expanded CD8+ T cells, thereby directly linking adaptive immune activation to neurodegeneration.

The Gist

The Big Picture: A Case of Mistaken Identity in the Body's Factory

Imagine your body is a massive, high-tech factory. Inside every cell, there is a Foreman named TDP-43. His job is to review the blueprints (DNA/RNA) before they are sent to the construction crew. He makes sure to cross out the "secret passages" or "hidden rooms" in the blueprints that aren't supposed to be built. These hidden passages are called cryptic exons.

In healthy people, the Foreman (TDP-43) stays in his office (the nucleus) and does his job perfectly. The blueprints are clean, and the factory builds normal proteins.

The Problem:
In diseases like ALS (affecting the brain and nerves) and IBM (affecting muscles), the Foreman gets sick. He leaves his office and wanders into the factory floor (the cytoplasm). Because he's gone, the "secret passages" in the blueprints are no longer crossed out.

The construction crew builds these secret passages anyway. This results in weird, new proteins that the body has never seen before. Think of these as "glitch monsters" or "alien artifacts" appearing in the factory.

The Discovery: The Security Guard Wakes Up

The body has a security team called CD8+ T cells. Their job is to patrol the factory and kill anything that looks like an invader.

For years, scientists knew that in ALS and IBM, these security guards were going crazy. They were multiplying rapidly and attacking the factory, but they didn't know what they were attacking. It was like a security guard screaming, "Get the bad guy!" but no one knew who the bad guy was.

This paper solved the mystery. The researchers found out exactly what the security guards were seeing: The Glitch Monsters.

How They Solved the Mystery

The researchers acted like detectives using three main tools:

1. Looking at the Crime Scene (Muscle Tissue):
   They took samples from patients with IBM. They found that in the muscle fibers where the Foreman (TDP-43) was missing, the "Glitch Monsters" (specifically a protein called HDGFL2) were piling up. Right next to these monsters, they found the security guards (T cells) and the "wanted posters" (MHC molecules) that display the monsters for the guards to see.

2. The High-Tech Scanner (Single-Cell Profiling):
   They took blood samples from ALS and IBM patients and ran them through a super-advanced scanner (called TetTCR-Seq). This scanner can look at millions of security guards at once and ask, "What are you looking for?"

   • The Result: They found that the guards were specifically targeting the "Glitch Monsters" (cryptic peptides from HDGFL2 and IGLON5). These guards were highly trained, specialized, and had multiplied into huge armies to fight these specific targets.

3. The Lab Test (The "Aha!" Moment):
   To prove it, they built a simulation in the lab:

   • They took a healthy cell and removed the Foreman (TDP-43) to make it "sick."
   • They took the specialized security guards (T cells) from a patient and gave them a "remote control" (a specific T-cell receptor) to recognize the Glitch Monster.
   • The Outcome: When the remote-controlled guards saw the sick cell, they immediately attacked and destroyed it. But if the cell was healthy (no glitch monster), the guards ignored it.

Why This Matters

This discovery changes how we view ALS and IBM.

• Old View: These diseases are just about the brain or muscles breaking down on their own.
• New View: The body's own immune system is accidentally attacking the brain and muscles because it sees the "Glitch Monsters" as dangerous invaders.

The Hope:
If we know exactly what the security guards are attacking, we can teach them to stand down. Instead of just trying to calm the whole immune system (which might leave the body vulnerable to real infections), doctors might be able to develop targeted therapies that specifically tell the T cells: "Stop attacking the HDGFL2 glitch. It's not a real enemy."

Summary Analogy

Imagine a castle where the King (TDP-43) stops giving orders. The guards start building secret, weird towers (cryptic peptides) that don't belong. The castle's defense system (T cells) sees these weird towers as enemy fortresses and starts shooting arrows at the castle walls, destroying the home.

This paper found the blueprints of the weird towers. Now, instead of just telling the guards to "stop shooting," we can show them the blueprints and say, "Those aren't enemy towers; they're just construction mistakes. Let's fix the construction process instead."

This opens the door for new, precise treatments that could stop the immune system from destroying the body in these devastating diseases.

Technical Summary

1. Problem Statement

Amyotrophic Lateral Sclerosis (ALS) and Inclusion Body Myositis (IBM) are neurodegenerative and myopathic disorders, respectively, characterized by the aggregation and nuclear depletion of the RNA-binding protein TDP-43.

• The Mechanism: TDP-43 normally represses "cryptic exons" (intronic sequences normally excluded from mRNA). When TDP-43 is depleted from the nucleus, these cryptic exons are aberrantly included in mRNA transcripts. While many lead to nonsense-mediated decay, some are translated into cryptic peptides (neo-proteins) that do not exist in healthy human physiology.
• The Immune Mystery: Recent studies have identified highly differentiated, clonally expanded CD8+ T cells in the blood and tissues of ALS and IBM patients, suggesting an antigen-specific adaptive immune response. However, the specific antigenic targets driving this response have remained elusive. It is unknown if these T cells are reacting to the cryptic peptides generated by TDP-43 loss.

2. Methodology

The authors employed a multi-modal approach combining tissue analysis, high-throughput single-cell profiling, and functional validation:

• Tissue Analysis (IBM Muscle):
  • Immunohistochemistry (IHC): Stained IBM muscle biopsies for TDP-43, p62 (aggregation marker), and a newly generated antibody against the HDGFL2 cryptic peptide.
  • Proteomics & RNA-seq: Analyzed mass spectrometry data and RNA sequencing from IBM muscle vs. controls to correlate cryptic exon expression with T cell infiltration (TCR/CD3) and MHC-I antigen presentation pathways.
• High-Throughput Single-Cell Profiling (TetTCR-SeqHD):
  • Used a proprietary DNA-barcoded pMHC tetramer technology to screen PBMCs from ALS and IBM patients.
  • Epitope Prediction: Computationally predicted 379 cryptic epitopes from 18 cryptic peptides across 9 HLA alleles.
  • Sorting & Sequencing: Sorted Tetramer+ CD8+ T cells and performed single-cell sequencing to capture TCR sequences, gene expression, and surface protein phenotypes simultaneously.
• Functional Validation:
  • TCR Engineering: Cloned TCRs from identified clones and transduced them into J76-CD8 reporter cells to test binding and activation (CD69 upregulation) against specific cryptic peptides.
  • Cytotoxicity Assays: Used an astrocyte cell line (CCF-STTG1) engineered to express GFP. The cells were either treated with siRNA to knock down TDP-43 (inducing cryptic exon expression) or transfected with specific cryptic epitopes. These were co-cultured with primary CD8+ T cells transduced with the identified TCRs to measure target cell killing.

3. Key Contributions

• Identification of Neo-Antigens: This is the first study to definitively link TDP-43 pathology to specific T cell antigens, identifying HDGFL2 and IGLON5 cryptic peptides as targets.
• Mechanistic Link: Demonstrates that TDP-43 loss leads to cryptic exon translation, which is processed and presented via MHC-I, triggering a cytotoxic CD8+ T cell response.
• Therapeutic Targeting: Proves that engineered T cells expressing these specific TCRs can recognize and kill TDP-43-deficient cells, validating the feasibility of antigen-specific immunotherapies for ALS/IBM.

4. Key Results

A. Cryptic Peptides in TDP-43 Pathology

• HDGFL2 Detection: In IBM muscle biopsies, the HDGFL2 cryptic peptide was detected in 9/10 patients but 0/4 controls. It co-localized with TDP-43 nuclear loss and p62 aggregates.
• Correlation with Immunity: The presence of HDGFL2 cryptic peptide correlated strongly with the expression of MHC-I pathway proteins and T cell markers (CD3, TCR). RNA-seq showed a strong correlation between the "burden" of cryptic exons and the expression of TCR and HLA genes.

B. Clonal Expansion of Cryptic-Specific T Cells

• Enrichment: CD8+ T cells binding cryptic epitope tetramers were significantly more frequent in ALS and IBM patients compared to healthy controls.
• Clonality: These cells were highly clonally expanded. In healthy donors, only ~3.7% of cryptic-specific cells were expanded, whereas in ALS/IBM patients, this rose to 31% and 37.8%, respectively. "Hyperexpanded" clones (>15 cells) were found only in patients.
• Phenotype: The cryptic-specific T cells exhibited a highly differentiated, cytotoxic phenotype (GZMK+ TEM and GNLY+ TEMRA), distinct from the naive-like phenotype seen in healthy controls.
• Specific Targets: Out of 11 high-confidence clones identified, 10 recognized epitopes derived from HDGFL2 or IGLON5.

C. Functional Validation of TCRs

• Binding & Activation: Two specific TCRs (TCR-4 from an IBM patient targeting HDGFL2; TCR-11 from an ALS patient targeting IGLON5) were engineered into reporter cells. They showed robust, specific binding to their cognate cryptic peptides and induced strong CD69 activation.
• Cytotoxicity:
  • TCR-4 engineered T cells killed astrocytes expressing the HDGFL2 cryptic epitope.
  • Crucially, when TDP-43 was knocked down in astrocytes (inducing endogenous HDGFL2 cryptic exon expression), TCR-4 engineered T cells efficiently killed these cells.
  • This killing was MHC-I dependent, as downregulating $\beta$2-microglobulin (MHC-I) abolished the cytotoxic effect.

5. Significance and Implications

• Paradigm Shift: This work redefines the pathogenesis of ALS and IBM, suggesting that the adaptive immune system is not just a bystander but an active driver of neurodegeneration via recognition of cryptic neo-antigens.
• Therapeutic Potential:
  • Antigen-Specific Therapy: Unlike broad immunosuppression, this opens the door for therapies that specifically dampen the response to cryptic peptides (e.g., tolerogenic vaccines or specific TCR blockade).
  • Cell Therapy: The study demonstrates that T cells can be engineered to target these specific antigens, suggesting a potential avenue for CAR-T or TCR-T therapies, though in this context, the goal would likely be to remove the pathogenic T cells or modulate their activity.
• Biomarkers: The HDGFL2 cryptic peptide serves as a potential biomarker for TDP-43 pathology and immune activation, detectable in muscle, CSF, and potentially blood.
• Clinical Context: The findings provide a mechanistic rationale for ongoing clinical trials using immunomodulators (e.g., low-dose IL-2, anti-KLRG1) in ALS/IBM, suggesting their efficacy may stem from modulating this specific cryptic-peptide-driven immune response.

In summary, the paper establishes a direct causal link between TDP-43 loss, the generation of cryptic neo-antigens, and a pathogenic CD8+ T cell response, offering a new molecular target for treating these devastating neurodegenerative diseases.